Thesis (Ph. D.)--University of Wisconsin--Madison, 1972. / Typescript. Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references.

Thesis (Ph. D.)--Ohio State University, 1972. / Includes vita. Includes bibliographic references (leaves 203-207). Available online via OhioLINK's ETD Center.

La presente tesis pretende utilizar el Método Harvard en la negociación comercial entre comprador y proveedor que sirva como herramienta, con el objetivo que el proveedor nos entregué los productos a tiempo, sin que haya desabastecimiento y así mismo poder obtener un mejor precio por ende poder obtener mejores ahorros. This thesis intends to use the Harvard Method in the commercial negotiation between buyer and supplier that serves as a tool, with the objective that the supplier delivered the products on time, without there being lack of supplies and likewise being able to obtain a better price thus obtaining better savings.

Analytic paper (Ed. D.)--Harvard Graduate School of Education, 1995. / Vita. eContent provider-neutral record in process. Description based on print version record. Includes bibliographical references (leaves 134-141).

Thesis--University of Wisconsin--Madison. / Typescript. Vita. Description based on print version record. Includes bibliographical references (leaves 273-294).

Thesis (M.B.)--Harvard University, 1789. / Signatures: [1]⁸. Not in Blake. NLM copy: closely trimmed along fore-edges, affecting text. Film 633 reel 72 is part of Research Publications Early American Medical Imprints collection (RP reel 72, no. 1470). DNLM DNLM Microform version available in the Readex Early American Imprints series.

Thesis (S.M.)--Harvard-MIT Division of Health Sciences and Technology, September 2006. / "August 2006." / Includes bibliographical references (leaves 37-38). / This work is an attempt to explain wide variations in drug licensing deal value by using regression modeling to describe and predict the relationship between oncology drug deal characteristics and their licensing deal values. Although the reasons for large variances in value between deals may not be immediately apparent, it was hypothesized that objective independent variables, such as a molecule's phase, its target market size and the size of the acquiring/licensor company could explain a significant portion of variation in cancer drug values. This model, although not predictive when used independently, could be used to supplement other discounted cash flow and market based techniques to help assess the worth of incipient oncology therapies. Using regression analysis to study drug licensing deals is not novel: a study was published by Loeffler et al in 2002 that attempted to assess the impact of multiple variables on deal value in a wide range of pharmaceutical indications. The independent variables in Loeffler's work could explain less than 50% of differences in deal values. It was expected that refining the model could lead to improved regression R squared coefficient and, potentially, be a useful tool for managers. This current work is based on the 2002 Loeffler paper, but differs significantly by: * Focusing on just oncology licensing deals instead of deals covering many indications, * Incorporating a measure of the assets of the larger licensee company, * Accounting for the licensing experience of the smaller licensor company, * Factoring in inflation and the years the deals were signed; and * Assessing the impact of primary indication market size. The goal of the thesis was to advance the art of estimating the value of drug licensing deals by assessing the impact of the aforementioned factors. / by Paul Allen Hawkins. / S.M.

Thesis (Ph. D.)--Harvard-MIT Division of Health Sciences and Technology, June 2007. / Includes bibliographical references (leaves 94-100). / Synaptic plasticity is the substrate of a vast variety of learning mechanisms. However, the molecular pathways and physiological patterns that regulate it are poorly understood. In the first part of this thesis, we focus on the physiological determinants of pre-synaptic plasticity. We find that a complete blockade of activity succeeds in inducing only a transient enhancement of plasticity. A permanent enhancement of synaptic plasticity is achieved by selectively reducing the NMDA-R mediated Ca2+ flux associated with uncorrelated activity, via adjustment of the voltage-dependent Mg2+ block of NMDA receptors. NR2B-containing NMDARs are up-regulated by this treatment, and this is found to be an important contributor to plasticity enhancement. Thus, the quality, but not the quantity, of activity is the important parameter to manipulate to obtain a permanent enhancement of intrinsic plasticity. In the second part, we study the relationship between activity patterns and postsynaptic NMDA-R regulation by using high-precision iontophoresis. We identified a new homeostatic mechanism of NMDA-R regulation which we have thus termed "NMDA Normalization" to differentiate it from prior uses of "NMDA homeostasis." Through this novel Ca++ dependent mechanism, we show that the neuron, by opposing NMDA-R functional expression counter to activity changes, causes the average charge transfer through NMDA-Rs to remain constant. We elucidate the activity-dependent, temporal, and spatial characteristics of this process. We propose an explanatory hypothesis. The reduction of uncorrelated activity used in the first part reduced the NMDA-R mediated average charge transfer. Through normalization, the cell increased functional NMDA-R expression to normalize NMDA-R mediated average charge transfer. However, when a burst of activity arrives in this new condition, in which an identical burst of glutamate release and depolarization now meets a larger number of very weakly activated NMDA-Rs, it is able to induce a disproportionately larger peak Ca++ flux. This increase in the maximal Ca++ flux, due to the combination of reduction of uncorrelated activity and NMDA-R normalization, is responsible in great part for the enhancement of synaptic plasticity. Our findings propose a clear strategy for the development of compounds to restore, and potentially enhance, synaptic plasticity, and thus with likelihood learning and memory. / Ph.D.

Thesis: Ph. D. in Medical Engineering, Harvard-MIT Program in Health Sciences and Technology, 2018. / Cataloged from PDF version of thesis. / Includes bibliographical references (pages 217-226). / The objective of this work was to develop materials for continuous low-dose delivery of cisplatin directly into the abdomen, also known as intraperitoneal (IP) chemotherapy. IP chemotherapy can help treat peritoneal metastasis in many advanced gynecologic and gastrointestinal cancers and has shown particular promise in treating advanced ovarian cancer. It is however tremendously underutilized because it requires a lot of resources and the current technology and maximum tolerated dose regimen cause complications and severe toxicity to patients. We previously showed that continuous low-dose IP cisplatin delivery via an implanted diffusion-based reservoir device can be as effective as and less toxic than intermittent maximum tolerated dose IP injections. To translate this work to a clinically relevant implantable system, we developed composite materials that can deliver cisplatin at a continuous low dose that is tunable. The materials were mechanically well suited for placement in the abdomen and were evaluated for in vitro bioactivity, in vivo tolerability and in vivo ability to deliver platinum to key abdominal organs with promising results. Dosing studies with different material dimensions helped identify a dose to pilot treatment of ovarian cancer in human xenograft-bearing mice. The implications of more accessible and affordable IP chemotherapy are especially important in countries with limited resources. Design reviews and a clinician survey in India reveal eagerness for early adoption of new technologies and dosing regimens to treat peritoneal metastasis and show promise for utilization of our implant in the developing world. The work described in this thesis carries implications for the treatment of advanced ovarian cancer and peritoneal metastasis of other tumors affecting millions of patients worldwide and may help with the management of nonmalignant conditions with abdominal involvement. / by Aikaterini Mantzavinou. / Ph. D. in Medical Engineering

Thesis (Ph.D.)--Harvard--Massachusetts Institute of Technology Division of Health Sciences and Technology, 1998. / Includes bibliographical references. / by James L. McGrath. / Ph.D.